Loading…
Loading…
Corient Private Wealth LP trimmed its position in shares of Axis Capital Holdings Limited (NYSE: AXS) by 18.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,879 shares of the insurance provider's stock after selling 15,155 shares during the quarter. Corient Private
PEMBROKE, Bermuda, Sept. 16, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited ("AXIS Capital" or the “Company”) (NYSE: AXS) today announced that its Board of Directors has declared a quarterly dividend of $0.44 per common share payable on October 15, 2026 to shareholders of record at the close of business on September 30, 2026.
LOS ANGELES & COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--AXS Joins AVA Presents to Power the Next Chapter of Colorado Springs' Historic CityAud.
LKQ, AGCO and AXS have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2026.
PEMBROKE, Bermuda, Sept. 08, 2026 (GLOBE NEWSWIRE) -- AXIS Capital Holdings Limited (“AXIS” or the “Company”) (NYSE: AXS) today unveiled a new brand campaign celebrating its 25-year history of providing specialty insurance and reinsurance solutions to customers. The company was formed in the aftermath of the September 11 tragedy to address a void in the market for specialist capacity. Since its modest beginnings as a start-up, AXIS has grown into a global specialty leader with $35 billion in total assets and $7.7 billion in total capital as of year-end 2025.
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in Smoking Cessation Treatment) is a Phase 3 randomized, double-blind, active- and placebo-controlled, multicenter trial to assess the efficacy and safety of AXS-05 as a smoking cessation treatment in adults.
Axis Capital (AXS) reported earnings 30 days ago. What's next for the stock?
SEC filings for AXS aren't indexed yet — common for recently launched funds. Browse the issuer's filings on SEC EDGAR directly.